Abstract 257P
Background
GTN comprises a unique group of tumours that originate from trophoblastic tissues which includes Invasive mole, choriocarcinoma and Placental site trophoblastic tumour and with proper treatment low-risk GTN is 100% curable. This study was carried out to evaluate the management outcome of low risk GTN patients to the accepted 1st line treatment regimens followed in the hospital.
Methods
205 patients of gestational trophoblastic disease who were registered at the institute between January 2016 and December 2018 were analysed retrospectively. Risk stratification & Staging was done according to Revised FIGO 2002 staging system. All low risk patients were included the study.
Results
Out of 205 ,46 (22%) patients were diagnosed with GTN (low-risk 43/205(21.5%). 37(86.04%) patients received single agent Methotrexate (weekly) while 4 (9.3%) patients received Actinomycin D (bi-weekly) as first line. Methotrexate/LV was given for 2 patients. 67.5%(n = 25/37) achieved Complete Response (CR) on Methotrexate while 32.4%(n = 12/37) went on to get second line.62.5%(n = 10/16) received ACT-D in second line while multi-drug chemotherapy was given to 5 patients (31%,5/16). CR was achieved in 84.62%(n = 11) in 2nd line while 1 patient went on to get 3rd line chemotherapy. Anemia was the most common complication associated with the disease and treatment.
Conclusions
Low- risk GTN is a highly chemo-sensitive tumor and 100% curable. methotrexate as single agent produced 67.5% of complete remission. Single agent methotrexate is still one of the preferred first-line regimes for low risk GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
The author has declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract